South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

litha pharma (pty) ltd - coated tablet - not indicated - each tablet contains propiverine hydrochloride equivalent to propiverine 5,0 mg

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - midazolam - injection - 5 mg/5 ml - midazolam 1 mg/ml

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - midazolam maleate 10.2mg eqv. to midazolam - tablet, film coated - 7.5mg

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - midazolam - injection - 15 mg/3 ml - midazolam 5 mg/ml

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - midazolam maleate 20.40 mg eqv. to midazolam - tablet, film coated - 15 mg - midazolam maleate 20.40 mg eqv. to midazolam 15 mg

European Union - English - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - hypercholesterolemia - lipid modifying agents - lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (ldl) apheresis in adult patients with homozygous familial hypercholesterolaemia (hofh). genetic confirmation of hofh should be obtained whenever possible. other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amryt pharma - lomitapide - capsule - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amryt pharma - lomitapide - capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amryt pharma - lomitapide - capsule - 20mg

Israel - English - Ministry of Health

medison pharma ltd - lomitapide as mesylate - capsules - lomitapide as mesylate 10 mg - lomitapide - an adjunct to a low-fat diet and other lipid-lowering treatments, including ldl apheresis where available, to reduce low-density lipoprotein cholesterol (ldl-c), total cholesterol (tc), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with homozygous familial hypercholesterolemia (hofh).